Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WEBSITE NEWS
January 17, 2005
- Pfizer Strengthens Ties with Customers via Territory Management System
January 17, 2005
- MEDICAL DEVICE NEWS IN BRIEF
January 17, 2005
- BUSINESS NEWS IN BRIEF
January 17, 2005
- New Year's Commentary
January 17, 2005
- WEBSITE NEWS
January 17, 2005
- NEW PRODUCTS
January 17, 2005
- Details on Japan-US Regulatory Reform Initiative Revealed: Korosho
January 17, 2005
- Non-ICH Countries Interested in GCP, Pharmacovigilance: Yokohama Meeting
January 17, 2005
- Korosho's Budget for Science, Technology to Hold Firm at \129 Bil.
January 17, 2005
- Monkasho's Draft Budget Earmarks \81.8 Bil. for Life Science
January 17, 2005
- For Innovation-Friendly and Patient-Oriented Healthcare
January 3, 2005
- Korosho Draft Budget Increases 3.1% to \20.8 Trillion
January 3, 2005
- Looking at the Year Ahead
January 3, 2005
- NEW PRODUCTS
January 3, 2005
- New year's Commentary
January 3, 2005
- Challenges Ahead for Everyone
January 3, 2005
- Blopress Passes Mevalotin as Top-selling Drug in 1st Half
January 3, 2005
- AstraZeneca Aims at Gaining 20% of Statin Market by Crestor: Dr Kato
January 3, 2005
- Tanabe Completes Enrollment of 1st 5,000 Remicade Users
January 3, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…